What’s Trending in Monoclonal Antibodies (Markets by Structure, by Target, and by Indication)
There are several types of monoclonal antibodies (mAbs) – large protein molecules produced by white blood cells (WBCs) that seek out and destroy harmful foreign substances – on the market and in development. What’s Trending in Monoclonal Antibodies looks at the market for these, which are finding wide application in many areas of medicine and biologic science, by structure, by target, and by indication, including the following information: monoclonal antibody revenues by structure, 2017 and forecast 2022 (chimeric, humanized, human, Others); leading chimeric, humanized and human mAb products market, 2017-2022; monoclonal antibody revenues by target, 2017 and forecast 2022 (TNF, CD20, HER2, VEGF, EGFR, PD-1, PD-L1, TNFSF11, IL12/IL23, IL17, IL6, Others); and monoclonal antibody revenues by indication, 2017 and Forecast 2022 (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other).
The report also goes beyond broad indication category to provide detail on the rheumatoid arthritis, Crohn’s disease/ulcerative colitis, psoriasis, other autoimmune, cancer (breast cancer, colon cancer, lymphoma, leukemia, myeloma, melanoma), multiple sclerosis, asthma, and macular degeneration mAb market segments, 2017-2022.
What’s Trending in Monoclonal Antibodies also looks at the market in terms of regional markets (United States, Europe, rest of world, global market) and the competitive situation, including company profiles of market leaders such as AbbVie, Johnson & Johnson, and Roche.